查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718018

学名药市场按产品类型、药品类别、给药途径、患者类型、治疗用途、分销管道划分 - 全球预测 2025-2030

Generic Drugs Market by Product Type, Drug Class, Route of Administration, Patient Type, Therapeutic Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年学名药市场规模将达到4,152.8亿美元，2025年将成长至4,516.1亿美元，复合年增长率为9.08%，到2030年将达到6,996.5亿美元。

主要市场统计数据
基准年2024年 4152.8亿美元
预计2025年 4516.1亿美元
预测年份 2030 6996.5亿美元
复合年增长率（%） 9.08%

学名药市场正在经历一段动态转型期，受技术进步、监管改革和对具有成本效益的患者照护的重视的推动。本报告深入探讨了创新与可负担性融合以迎来下一波医药突破的市场格局。过去几年，市场参与企业克服了严格的法规环境带来的挑战，同时平衡了对优质替代治疗方案的需求。从製造商到医疗保健提供者的相关人员现在都专注于重新思考他们的策略，以利用已开发市场和新兴市场中尚未开发的商业机会。

这一发展的背后是人们对学名药的经济和治疗价值的认识不断提高。製造商不断努力改进生产流程、创新配方模板，并更快地将更安全、更有效的替代品推向市场。认识的提高、政策的支持以及对医疗保健可及性的强烈推动正在激发人们对学名药的兴趣，从而加速其增长轨迹并培育更健康的竞争格局。目前的市场环境要求我们不仅生产具有成本效益的药物，还要提供科学合理的替代品，以更全面地满足患者的需求。

这份综合报告深入探讨了市场区隔、区域趋势、竞争基准化分析和策略建议等关键领域。本报告重点介绍了变革性变化和关键见解，以帮助决策者了解学名药领域的机会和挑战。随着新技术和新治疗需求塑造产业，本简报为如何最好地应对未来市场情景的知情讨论提供了一个平台。

变革性变化重新定义学名药产业

学名药领域正在经历剧变，重新定义市场动态和竞争模式。技术进步、不断发展的法规结构以及全球医疗保健政策的变化共同创造了一个以敏捷和创新为特征的市场环境。製造业的快速数位化和自动化以及配方科学的突破不仅提高了业务效率，而且显着缩短了生产週转时间。此类技术干预使公司能够满足对高品质且价格合理的药品不断增长的需求，同时保持严格的安全标准，从而促进了市场的发展。

世界各地的监管机构正在采用更灵活和更具适应性的框架，鼓励製造商在不影响品质的情况下加快产品平臺的开发。这些努力使公司能够探索进入市场的替代途径，并促进更快地获得更多种类的学名药。包括製造商、研究机构和政策制定者在内的各相关人员之间的合作进一步凸显了这种适应性，这在解决全球製药业固有的复杂问题方面发挥关键作用。

此外，个人化医疗的兴起和慢性病的流行也刺激了对有效且经济实惠的替代疗法的需求。在必须快速适应新的医疗保健挑战的生态系统中，该行业正在经历向以患者为中心的方法的决定性转变。与这些趋势同时，采用数据分析和先进的市场研究技术使企业能够即时了解消费行为和需求模式，从而改善其策略倡议。

目前正在进行的转变显然是多方面的、影响深远的。背后的驱动力是需要解决民众的成本敏感性以及满足更广泛的治疗需求。因此，公司正在从传统的基于数量的业务模式转向更具创新性的、以品质为导向的模式。这种演变凸显了一种更广泛的趋势，即先进技术与强有力的监管支持的结合为学名药市场的性能和创新树立了新的基准。

学名药市场的关键细分洞察

彻底的細項分析为了解影响学名药市场的驱动因素和障碍提供了宝贵的见解。首先，在评估产品类型时，我们透过区分非处方学名药和处方学名药来分析市场。这种细分使得市场参与者能够根据客户访问动态和监管考虑来缩小他们的方法。除了按产品类型进行二分法评估外，还按药物类别进行评估，包括镇痛药、抗生素、抗忧郁症、抗糖尿病药、抗组织胺和抗高血压药等治疗物质。这些类别至关重要，因为它们反映了解决不同人群中普遍存在的健康问题的核心领域。

进一步细分，给药途径有复杂的考虑，例如吸入、注射、口服和外用。每种给药途径都有不同的临床目标并满足不同的患者需求，每种途径在监管核准和市场渗透方面都面临独特的挑战。透过详细了解涵盖成人、老年人和儿童人口统计的患者类型，可以进一步增强策略洞察力，突显不同年龄层不断变化的治疗需求。这些见解使製造商和经销商能够客製化产品以满足特定人口需求。

此外，治疗应用在细分中起着至关重要的作用，因为市场可以透过抗感染药感染疾病、心血管药物、中枢神经系统（CNS）药物、抗糖尿病药物、肿瘤药物、呼吸系统药物等类别来观察。深入了解这些治疗领域不仅会突显产品差异化，还会提高您的市场策略的相关性。最后，我们透过区分线下药局和线上药局来检查分销管道。线下部分进一步分为医院药房和零售药房，每个部分都有不同的营运细节和市场动态。透过这种多层次的细分，可以识别并策略性地瞄准成长动力和潜在机会。

透过这种全面的细分，产业相关人员可以更清楚地了解消费行为、监管挑战和竞争格局。分析强调，多方面的细分策略对于使产品开发、上市和分销策略与学名药领域的新兴市场需求保持一致至关重要。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 政府采取优惠倡议，推广学名药的使用，以降低医疗成本
      • 生物相似药投资增加推动学名药市场成长
      • 慢性病盛行率上升推动了对可负担且可获得的药物的需求
    • 限制因素
      • 对学名药品质、功效和安全性的担忧正在影响仿製药的采用
    • 机会
      • 药品专利到期为学名药上市创造巨大机会
      • 学名药：透过药品生产製程创新降低成本并提高质量
    • 任务
      • 严格的监管要求和核准时间对学名药製造商构成挑战
  • 市场区隔分析
    • 产品类型：消费者可近性和可负担性推动了对非处方 (OTC)学名药的需求
    • 药物类别：增加抗忧郁症的使用，以提高患者的依从性和治疗效果
    • 给药途径：口服给药，方便且病人接受度高
    • 病患类型：老年患者使用的锭剂和液体製剂学名药
    • 治疗应用：口服降血糖药和胰岛素学名药的采用
    • 分销管道：便利性和个人化服务是推动线下分销通路偏好的因素
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章学名药市场（依产品类型）

  • 非处方（OTC）学名药
  • 处方笺学名药

第七章学名药市场（依药品类别）

  • 止痛药
  • 抗生素
  • 抗忧郁症
  • 抗糖尿病药物
  • 抗组织胺药
  • 抗高血压药

第八章学名药市场（依给药途径）

  • 吸入
  • 注射
  • 口服
  • 话题

第九章学名药市场（依患者类型）

  • 对于成年人
  • 老年人
  • 小儿科

第 10 章学名药市场（依治疗应用）

  • 抗感染药物
  • 心血管系统
  • 中枢神经系统（CNS）
  • 糖尿病
  • 肿瘤学
  • 呼吸系统

第十一章学名药市场（按分销管道）

  • 离线
    • 医院药房
    • 零售药局
  • 网路药局

第 12 章：美洲学名药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章：亚太地区学名药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲学名药市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Alembic Pharmaceuticals Limited
  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo, Inc.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC.
  • Intas Pharmaceuticals Ltd.
  • Krka, dd
  • Lupin Limited
  • Pfizer, Inc.
  • Sandoz Group AG
  • Sanofi SA
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-F6513A06BE93

The Generic Drugs Market was valued at USD 415.28 billion in 2024 and is projected to grow to USD 451.61 billion in 2025, with a CAGR of 9.08%, reaching USD 699.65 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 415.28 billion
Estimated Year [2025] USD 451.61 billion
Forecast Year [2030] USD 699.65 billion
CAGR (%) 9.08%

The generic drugs market has witnessed an era of dynamic transformation, underpinned by advancements in technology, regulatory reforms, and an ever-increasing emphasis on cost-effective patient care. This report embarks on a detailed exploration of the market landscape where innovation meets affordability, driving the next wave of pharmaceutical breakthroughs. Over the past few years, market participants have navigated challenges from stringent regulatory environments while balancing the need for high-quality therapeutic alternatives. Stakeholders across the board-from manufacturers to healthcare providers-are now focusing on refining strategies to harness untapped opportunities in both developed and emerging markets.

Underpinning this progress is a growing recognition of the economic significance and therapeutic value of generic drugs. Manufacturers are continually striving to improve the production processes, innovate templates for drug formulations, and rapidly bring safe, efficacious alternatives to market. Increased awareness, policy support, and a robust drive towards making healthcare accessible are stimulating interest in generic drugs, thereby accelerating growth trajectories and fostering healthier competitive landscapes. The current market environment is not merely about producing cost-effective drugs; it is about delivering scientifically robust alternatives that meet patient demands more holistically.

In this comprehensive report, we dive deep into pivotal areas such as market segmentation, regional trends, competitive benchmarking, and strategic recommendations. The discussion elucidates transformative shifts and critical insights which help decision-makers understand both opportunities and challenges ahead in the generic drugs segment. As emerging technologies and novel therapeutic demands shape the industry, this brief sets the stage for an informed debate on how best to address future market scenarios.

Transformative Shifts Redefining the Generic Drugs Sector

The landscape of the generic drugs industry is undergoing seismic shifts that are redefining market dynamics and competitive paradigms. Technological advancements, evolving regulatory frameworks, and shifts in global healthcare policies are interweaving to create a market environment marked by agility and innovation. Rapid digitalization and automation in manufacturing, alongside breakthroughs in formulation science, have not only augmented operational efficiencies but also significantly reduced production turnaround times. These technological interventions have catalyzed the market by enabling firms to meet the soaring demand for high-quality yet affordable medicines, while simultaneously maintaining rigorous safety standards.

Regulatory bodies across the globe have adopted more flexible and adaptive frameworks, encouraging manufacturers to expedite their product pipelines without compromising on quality. Such initiatives have allowed companies to explore alternative routes to market, facilitating faster entry for a wider range of generic therapies. This adaptability is further highlighted by collaborations between various stakeholders-including manufacturers, research institutions, and policy-makers-which are instrumental in navigating the complexities inherent in the global pharmaceuticals arena.

Moreover, the rise of personalized medicine and increased prevalence of chronic conditions have spurred demand for therapeutic alternatives that are both effective and affordable. Amid an ecosystem that now necessitates swift responses to emergent healthcare challenges, the industry has seen a decisive shift towards patient-centric approaches. In tandem with these trends, the deployment of data analytics and advanced market research techniques has enabled companies to gain real-time insights into consumer behavior and demand patterns, thereby refining their strategic initiatives.

The ongoing transformation is clearly multifaceted and far-reaching. It is driven by the need not only to cater to the cost sensitivities of populations but also to address a broader spectrum of therapeutic requirements. Consequently, companies are pivoting from traditional, volume-based operational models to more innovative, quality-focused paradigms. This evolution underscores a broader trend wherein the integration of advanced technologies with robust regulatory support is setting a new benchmark for performance and innovation in the generic drugs market.

Key Segmentation Insights in the Generic Drugs Market

A thorough segmentation analysis offers valuable perspectives on the drivers and barriers that are influencing the generic drugs market. First, when evaluating the product type, the market is analyzed by distinguishing between over-the-counter generic drugs and prescription generic drugs. This delineation enables market players to refine their approaches based on customer access dynamics and regulatory considerations. In addition to the dichotomy of product types, the evaluation extends to drug class, which encompasses an array of therapeutic substances such as analgesics, antibiotics, antidepressants, antidiabetics, antihistamines, and antihypertensives. These categories are of utmost importance as they reflect the core areas of focus in addressing prevalent health concerns across diverse populations.

Further segmentation explores the route of administration, which involves an intricate examination of inhalations, injectables, oral, and topical formulations. Each route serves a different clinical purpose and caters to distinct patient needs, with each modality presenting unique challenges in regulatory approval and market penetration. The detailed consideration of patient type-covering adult, geriatric, and pediatric demographics-further sharpens the strategic insights by highlighting the evolving treatment requirements across age groups. Such insights allow manufacturers and distributors to customize their offerings to meet specific demographic needs.

Moreover, therapeutic application plays a critical role in segmentation as the market is observed through categories including anti-infectives, cardiovascular, central nervous system (CNS) drugs, diabetes, oncology, and respiratory treatments. A deep understanding of these therapeutic areas not only emphasizes product differentiation but also enhances the relevance of market strategies. Lastly, distribution channels are scrutinized by distinguishing between offline and online pharmacies. The offline segment further bifurcates into hospital pharmacies and retail pharmacies, each with its operational nuances and market dynamics. This layered approach to segmentation helps in identifying growth drivers and potential pockets of opportunity that can be strategically targeted.

Through this comprehensive segmentation, industry stakeholders can gain a clearer understanding of consumer behavior, regulatory challenges, and the competitive environment. The analysis underscores that a multi-dimensional segmentation strategy is essential for aligning product development, market entry, and distribution strategies with the evolving market demands in the generic drugs sector.

Based on Product Type, market is studied across Over-the-Counter (OTC) Generic Drugs and Prescription Generic Drugs.

Based on Drug Class, market is studied across Analgesics, Antibiotics, Antidepressants, Antidiabetics, Antihistamines, and Antihypertensives.

Based on Route of Administration, market is studied across Inhalations, Injectables, Oral, and Topical.

Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.

Based on Therapeutic Application, market is studied across Anti-infectives, Cardiovascular, Central Nervous System (CNS), Diabetes, Oncology, and Respiratory.

Based on Distribution Channel, market is studied across Offline and Online Pharmacies. The Offline is further studied across Hospital Pharmacies and Retail Pharmacies.

Regional Trends Shaping Generic Drugs Dynamics

Analysis of the market by region offers granular insights into the diverse challenges and opportunities inherent in the generic drugs industry. Distinct trends in the Americas have showcased an aggressive push towards the adoption of cost-effective medications, driven by both policy support and robust healthcare infrastructure. The region has consistently demonstrated a high level of consumer trust in generic alternatives, and market strategies in this area are focused on innovation, quality assurance, and competitive pricing mechanisms.

In the Europe, Middle East & Africa region, market dynamics have been shaped by a balance between historical regulatory frameworks and rapidly emerging technological trends. Although the regulatory environment remains stringent, continuous efforts towards streamlining approval processes have fostered growth. The diversity in economic development and healthcare infrastructure across these areas necessitates a tailored approach, where strategies are adapted not only to meet regulatory compliances but also to address the diverse economic challenges of the region.

Similarly, the Asia-Pacific region has emerged as a significant growth driver in the global generic drugs market. Rapid urbanization, increased healthcare expenditures, and an upsurge in awareness about affordable pharmacotherapies have collectively fueled market growth. The region's unique ability to leverage economies of scale, coupled with an expanding pool of research and innovation, is transforming it into a powerhouse of generic drug manufacturing and distribution. Such regional disparities and growth patterns provide a comprehensive understanding of where the opportunities and challenges lie in different geographical terrains.

Collectively, these regional insights are pivotal for companies seeking to tailor their strategic initiatives. By leveraging detailed regional analysis, market leaders can develop targeted strategies that account for economic, cultural, and regulatory nuances, thereby optimizing their market penetration efforts and ensuring long-term sustainability.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving the Market Momentum

A competitive analysis of the market reveals a robust lineup of companies that have emerged as key players, driving innovation, quality, and market expansion in the generic drugs space. Industry leaders such as Abbott Laboratories, Alembic Pharmaceuticals Limited, and Alkem Laboratories Limited set high benchmarks through rigorous quality control measures and strategic outreach. Firms like Amneal Pharmaceuticals, Inc. and Aspen Pharmacare Holdings Limited have consistently invested in research and development to secure a competitive edge, adapting swiftly to market changes and regulatory requirements.

Furthermore, companies including Aurobindo Pharma Limited, Bausch Health Companies Inc., and Baxter International Inc. have leveraged advanced manufacturing processes to deliver cost-effective therapeutics without compromising on quality. These organizations continuously refine their product portfolios to cater to an increasingly demanding market base that spans varied therapeutic classes and patient segments. Industry titans such as Biocon Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., and Eli Lilly and Company have pooled their expertise to navigate complex market dynamics, ensuring that innovative yet affordable therapeutic solutions remain accessible to diverse populations.

In addition, the presence of major entities like Endo, Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, and Glenmark Pharmaceuticals Limited highlights the market's intensive focus on quality and strategic partnerships. These companies have been instrumental in championing advancements across drug classes including central nervous system (CNS) therapies and chronic disease management solutions. Notably, forward-thinking players such as Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., and Krka, d. d. have embraced digitization and process optimization to further enhance their market position.

The role of global powerhouses such as Lupin Limited, Pfizer, Inc., Sandoz Group AG, Sanofi SA, and STADA Arzneimittel AG is equally significant as they expand their generic drug portfolios to incorporate breakthrough therapies. The competitive dynamics are further enriched by the sustained efforts of Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Limited, who continue to enhance market accessibility and affordability. This competitive landscape drives all players to continuously innovate and evolve, ultimately shaping the market's trajectory in significant ways.

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Amneal Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Bausch Health Companies Inc., Baxter International Inc., Biocon Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo, Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC., Intas Pharmaceuticals Ltd., Krka, d. d., Lupin Limited, Pfizer, Inc., Sandoz Group AG, Sanofi SA, STADA Arzneimittel AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Limited. Strategic Recommendations for Market Stakeholders

For industry leaders aiming to consolidate their market position and capitalize on emerging opportunities, several strategic recommendations emerge from the comprehensive analysis. Firstly, a deep commitment to research and development is essential. Investing in advanced manufacturing technologies, fostering innovation in drug formulations, and streamlining production processes can result in significant competitive advantages, ensuring that generic drugs remain safe, effective, and affordable.

Secondly, establishing robust strategic partnerships is key. Collaborations with technology providers, research institutions, and key opinion leaders can facilitate access to cutting-edge insights and capabilities. This collaborative approach enables companies to quickly adapt to shifting market dynamics and regulatory requirements, thereby enhancing time-to-market for generics that address critical therapeutic needs.

Further, market stakeholders need to place an emphasis on segmentation-driven strategies. By leveraging robust segmentation models that encompass product types, drug classes, routes of administration, patient types, therapeutic applications, and distribution channels, companies can devise targeted strategies that resonate with specific consumer needs. Such stratified approaches allow for the optimization of resources and the tailoring of marketing initiatives, ensuring that the right product is available to the right patient at the right time.

Another recommendation is to adopt data-driven decision-making frameworks. Harnessing advanced analytics and market intelligence can provide real-time insights that inform strategic planning and operational execution. This can lead to better demand forecasting, improved inventory management, and more effective pricing strategies that align with market dynamics in various regions.

Finally, companies should focus on regulatory agility and an adaptive approach to compliance. In a market that is subject to diverse and evolving regulatory conditions across geographies, maintaining compliance while ensuring innovation is a delicate balancing act. Proactive engagement with regulatory bodies and continuous monitoring of policy changes will help manufacturers to swiftly adapt and maintain market credibility. These actionable steps, when combined with a long-term strategic vision, can empower market leaders to not only navigate current challenges but also to spearhead future innovations in the generic drugs landscape.

Concluding Strategic Insights in the Generic Drugs Market

In summary, the generic drugs market is poised at a pivotal crossroad underscored by rapid technological advancements, evolving regulatory frameworks, and a clear shift towards patient-centric therapeutic solutions. The comprehensive analysis presented here underscores a fervent movement away from traditional operational models, making way for innovative approaches that emphasize quality, efficiency, and strategic segmentation. By understanding the intricacies of market dynamics-from robust regional trends to the competitive maneuvers of industry frontrunners-stakeholders can chart a clearer path to sustained growth and market relevance.

The journey ahead is marked by both challenges and vast opportunities. Success in this market will depend on the ability to adapt to rapid changes, leverage data-driven insights, and forge strategic partnerships that drive innovation. Ultimately, embracing these insights will not only help in navigating today's complexities but also in shaping a resilient and forward-looking framework for the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Favorable government initiatives promoting the use of generic drugs to reduce healthcare expenditure
      • 5.1.1.2. Increasing investments in biosimilar development driving growth in the generic drugs market
      • 5.1.1.3. Rising prevalence of chronic diseases propels demand for affordable and accessible medications
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over the quality, efficacy, and safety of generic drugs impacting their adoption
    • 5.1.3. Opportunities
      • 5.1.3.1. Patent expirations of drugs creating significant opportunities for the launch of generic alternatives
      • 5.1.3.2. Innovations in drug manufacturing processes to reduce costs and improve the quality of generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and approval timelines posing challenges for generic drug manufacturers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing need for over-the-counter (OTC) generic drugs due to high consumer accessibility and affordability
    • 5.2.2. Drug Class: Rising usage of antidepressants to enhance patient adherence and therapeutic outcomes
    • 5.2.3. Route of Administration: Utilization of oral route due to its convenience and widespread patient acceptance
    • 5.2.4. Patient Type: Utilization of generic drugs in geriatric type for tablets and liquid formulations
    • 5.2.5. Therapeutic Application: Adaoption of diabetes generic drug in oral hypoglycemics and insulin
    • 5.2.6. Distribution Channel: Growing preference for offline distribution channels due to convenience and personalized service
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Drugs Market, by Product Type

  • 6.1. Introduction
  • 6.2. Over-the-Counter (OTC) Generic Drugs
  • 6.3. Prescription Generic Drugs

7. Generic Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Analgesics
  • 7.3. Antibiotics
  • 7.4. Antidepressants
  • 7.5. Antidiabetics
  • 7.6. Antihistamines
  • 7.7. Antihypertensives

8. Generic Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalations
  • 8.3. Injectables
  • 8.4. Oral
  • 8.5. Topical

9. Generic Drugs Market, by Patient Type

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Generic Drugs Market, by Therapeutic Application

  • 10.1. Introduction
  • 10.2. Anti-infectives
  • 10.3. Cardiovascular
  • 10.4. Central Nervous System (CNS)
  • 10.5. Diabetes
  • 10.6. Oncology
  • 10.7. Respiratory

11. Generic Drugs Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Offline
    • 11.2.1. Hospital Pharmacies
    • 11.2.2. Retail Pharmacies
  • 11.3. Online Pharmacies

12. Americas Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Generic Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Generic Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Hikma launches generic liraglutide injection after FDA approval
    • 15.3.2. FDA approves generic Nilotinib for chronic myeloid leukemia
    • 15.3.3. BC partners majority stake in generics leader Synthon to Goldman Sachs alternatives
    • 15.3.4. Penn Medicine collaborates with Mark Cuban's Cost Plus Drugs to enhance generic drug accessibility
    • 15.3.5. Glenmark expands its ophthalmic portfolio with the launch of travoprost, a cost-effective glaucoma treatment
    • 15.3.6. Sunshine Biopharma expands Canadian market presence with ursodiol launch
    • 15.3.7. Gilead partners with global generic drugmakers to enhance affordable HIV treatment accessibility
    • 15.3.8. Platinum Equity acquires major stake in Inventia Healthcare to bolster global generics presence
    • 15.3.9. Cipla secures final approval for generic drug version
    • 15.3.10. Zydus Lifesciences enters US market with generic overactive bladder medication
    • 15.3.11. ChrysCapital's strategic investment in La Renon aims to strengthen its position in the generic drug market
    • 15.3.12. Cosmos Health strengthens position in generics market with strategic acquisition
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Cipla Limited
    • 15.4.2. Teva Pharmaceutical Industries Ltd.
    • 15.4.3. Abbott Laboratories
    • 15.4.4. Sun Pharmaceutical Industries Limited

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alembic Pharmaceuticals Limited
  • 3. Alkem Laboratories Limited
  • 4. Amneal Pharmaceuticals, Inc.
  • 5. Aspen Pharmacare Holdings Limited
  • 6. Aurobindo Pharma Limited
  • 7. Bausch Health Companies Inc.
  • 8. Baxter International Inc.
  • 9. Biocon Limited
  • 10. Cipla Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. Endo, Inc.
  • 14. Fresenius SE & Co. KGaA
  • 15. GlaxoSmithKline PLC
  • 16. Glenmark Pharmaceuticals Limited
  • 17. Hikma Pharmaceuticals PLC.
  • 18. Intas Pharmaceuticals Ltd.
  • 19. Krka, d. d.
  • 20. Lupin Limited
  • 21. Pfizer, Inc.
  • 22. Sandoz Group AG
  • 23. Sanofi SA
  • 24. STADA Arzneimittel AG
  • 25. Sun Pharmaceutical Industries Limited
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Viatris Inc.
  • 28. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. GENERIC DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. GENERIC DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY OVER-THE-COUNTER (OTC) GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY PRESCRIPTION GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIDIABETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM GENERIC DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 330. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 331. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024